AbbVie is doubling down on cancer drugs and stateside manufacturing, rolling out a pair of moves that stretch from China’s biotech scene to an industrial site in Tempe, Arizona. On Monday, the company inked an exclusive ex-China licensing deal with Yantai-based RemeGen for the experimental antibody RC148 and separately announced plans to buy and overhaul a device-manufacturing plant in Tempe. AbbVie will pay $650 million up front for RC148, with the program potentially delivering billions more if a slate of clinical and commercial milestones pans out. Together, the steps highlight AbbVie’s push to deepen its oncology portfolio while beefing up U.S. production capacity.
In a Jan. 12 statement, AbbVie said it has secured exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China and will pay RemeGen $650 million up front. Under the agreement, RemeGen may receive up to $4.95 billion in additional development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on sales of RC148 outside China.
What RC148 Is
RC148 is a bispecific antibody that targets PD-1 and VEGF and is being tested both on its own and in combination regimens across several advanced solid tumors, including non-small cell lung cancer and colorectal cancer, according to Reuters. Early clinical data have shown initially favorable antitumor activity, especially when RC148 was paired with antibody-drug conjugates in early-stage studies.
Deal Follows China Licensing Spree
The RemeGen pact slots into a broader run of China-linked oncology deals for AbbVie. The company recently signed an option agreement that included roughly $100 million up front for alveltamig (ZG-006), as reported by Fierce Biotech. Industry watchers note that these sorts of licensing structures let big drugmakers plug clinical-stage assets into their pipelines without taking on the full cost and complexity that come with outright acquisitions.
U.S. Manufacturing Push
On the homefront, AbbVie also announced it will acquire and modernize a device-manufacturing facility in Tempe, Arizona, with plans to invest more than $175 million and hire about 200 employees, according to a company release posted on PR Newswire. AbbVie framed the facility purchase as another step in a previously outlined commitment to invest more than $10 billion in U.S. manufacturing over the next decade, a development also picked up by Crain's Chicago Business.
Regulatory Outlook and Risks
AbbVie and RemeGen both stressed that RC148 is still investigational and that any meaningful commercial payoff depends on future clinical results and regulatory green lights. Each company included standard caveats about forward-looking statements in its communications. "By combining the immune checkpoint inhibition and anti-angiogenic activity of RC148 together with the targeted cytotoxic activity of ADCs, we have the potential to identify meaningful options for patients across a range of solid tumors," Daejin Abidoye, AbbVie’s vice president and therapeutic area head for oncology, said in AbbVie. The financial promise of the deal will ultimately ride on clinical evidence and regulatory decisions in multiple regions.
Investors and clinicians will be watching closely as more RC148 trial data emerge and as AbbVie signals whether it will formally advance combinations of the antibody with its own antibody-drug conjugates. For now, the multibillion-dollar headline numbers are just that: headlines. It will take future filings, readouts and company disclosures to show whether these moves translate into real-world cancer treatments and sustainable revenue.
